http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8324280-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd29014c4b0304838a856e8a0b992941 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a135a933620c99beab01d4ac785d25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c6bc9d6ada2502e01520adef3f7342b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197 |
| filingDate | 2009-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62023221a7dc39cd43b615e77ff6cd3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c34f9386c59a83cf3f742a94b5879ad1 |
| publicationDate | 2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8324280-B2 |
| titleOfInvention | Treatment of prostate cancer with DDC inhibitor |
| abstract | Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10064834-B2 |
| priorityDate | 2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.